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ABSTRACT

Highly reactive radical species such as hydroxyl radical cause oxidative stress,
resulting in chronic or degenerative diseases. In the biological Fenton reaction, iron(II)
generates hydroxyl radical, OH, but only within a specific electrochemical potential
window (-324 mV to 640 mV). Selenium and sulfur compounds have been extensively
studied for their antioxidant properties, and they may exert their effects by binding
iron(II) and shifting its electrochemical potential out of this window. This work has
investigated the synthesis and electrochemical characterization of iron(II) chalcogenate
complexes and iron(II) chalcogenone complexes.

Cyclic voltammetry (CV) of

[Fe(EPh)4][(PPh4)2] (E = S, Se) complexes shows Fe2+/3+ redox potentials of -723 mV (E
= S) and -1010 mV (E = Se) vs. NHE. These electrochemical results suggest that
selenium coordination stabilizes iron(II) relative to sulfur coordination and may inhibit
iron redox cycling.
Because of synthetic difficulties with iron(II) complexes, ruthenium(II) was
substituted for iron(II) due to its inert reaction kinetics and diamagnetism, allowing the
use of NMR spectroscopy for characterization. Tris(pyrazolyl)methane ruthenium(II)
complexes of the formula [TpmRRu(NCCH3)3]2+ (R = Me, Ph) and the previouslyreported tris(pyrazolyl)borate ruthenium(II) complexes [TpRRu(NCCH3)3]+ (R = H, Me,
Ph) have been synthesized using a new synthetic pathway that reduces the number of
required steps on average by 80% and average reaction times by over 95%.
Tris(pyrazolyl) (Tp) ligands are used to mimic adenine and guanine coordination to
ruthenium(II), known sites of metal localization. CV studies of [TpRu(NCCH3)3][BF4]
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(Tp

=

tris(pyrazolyl)borate)

and

[Tp*Ru(NCCH3)3][OTf]

(Tp*

=

tris(3,5-

dimethylpyrazolyl)borate) determined Ru2+/3+ redox potentials of 489 mV and 498 mV,
respectively, vs. NHE compared to the Ru2+/3+ redox potential for [Ru(NCCH3)6][(BF4)2]
of 517 mV.

Thus, coordination of Tp-type ligands substantially affects the redox

chemistry of ruthenium as well as iron.
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CHAPTER ONE
A BRIEF REVIEW OF THE USES OF IRON AND RUTHENIUM COMPLEXES
WITH TRIS(PYRAZOLYL) LIGANDS AND THEIR BIOLOGICAL RELEVANCE

Introduction
Iron is an essential metal that is required for the activity of enzymes and proteins.
It is vital in the transport O2 throughout mammalian organisms in hemoglobin,1 in the
electron transport chain of cellular respiration in cytochrome,2 and the degradation of
hydrogen peroxide into oxygen and water in catalase.3 As a transition metal, nonprotein-bound iron is prone to electron transfer reactions that enable it to generate
reactive oxygen species (ROS). This labile iron participates in the Fenton reaction
generating the ROS hydroxyl radical, OH (Figure 1.1). Labile iron(II) generates OH by
reducing hydrogen peroxide (a byproduct of cellular respiration), thereby oxidizing iron
from a +2 oxidation state to +3. Iron(III) is then reduced back to iron(II) by cellular
reductants such as nicotinamide adenine dinucleotide (NADH) to complete the cycle.4

Figure 1.1. The Fenton reaction in biological systems.

1

The generated hydroxyl radical can cause oxidative stress in cells, damage to
lipids and proteins, and damage to DNA.5 Hydroxyl radical has been identified as a
primary cause of increased risk of life-threatening and chronic or degenerative diseases
such as cancer,6 as well as cardiovascular,7 Alzheimer’s,8 and Parkinson’s diseases8-12
and is a primary factor in the aging process.13 Therefore, it is of great interest to
investigate methods to prevent the formation of hydroxyl radical for disease prevention
and treatment.
Many types of DNA modifications are caused by OH,14,15 and several of the OHinduced DNA modifications are mutagenic.16

DNA damage from hydroxyl radical

occurs at the nucleotide bases and the phosphate backbone via strand breakage.17 In
cells, positively-charged iron ions localize around the negatively-charged phosphate
backbone to help stabilize the charge of the oxygen atoms18 and electron-rich nucleotide
bases (specifically at guanine-rich sequences)19-21 through electrostatic interactions
(Figure 1.2). When hydrogen peroxide is in close proximity to localized iron(II) on the
DNA phosphate backbone, OH is formed and can deprotonate the backbone at the 4’
carbon, resulting in a rearrangement reaction that ultimately cleaves the phosphodiester
bond between deoxyribose sugars and DNA backbone cleavage.18,19,21,22
N,N,N-type donor ligands have been of interest in metalloenzyme modeling,
specifically with 2-His-1-carboxylate functionality (Figure 1.3) commonly found in
enzymes that contain non-heme iron(II).23 These ligands coordinate a wide variety of
metal centers, specifically late 1st row transition metals. Two widely used ligands of the
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Figure 1.2. (A, left) NMR structure of ATGA segment (red) from DNA showing Fe2+
(orange) bound to the N7 of the guanine base and its proximity to the cleaved thymidine
deoxyribose (yellow), used with permission.20 (A, right) Fe2+ binding to an ATGA
segment, drawn for clarity. (B, left) NMR structure the AGGG segment (A in green and
GGG in pink) from DNA showing Fe2+ (orange) bound to the N7 of the guanine bases
and its proximity to the cleaved thymidine deoxyribose (yellow), used with permission.22
(B, right) Fe2+ binding to an AGGG segment, drawn for clarity.
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N,N,N-type are tris(pyrazolyl)borates (TpR; 1; Figure 1.4) and tris(pyrazolyl)methanes
(TpmR; 2; Figure 1.4). First synthesized by Trofimenko, Tp and Tpm coordinate to 1st
and 2nd row transition metals, and the properties of these complexes have been
extensively studied in terms of structural characterization, reactivity, and electronic
properties.24 Trofimenko and Kitajima have used tris(pyrazolyl)borate (Tp) complexes
with N,N,N donor ligands to model several enzymes with the 2-His-1-carboxylate facial
triad; however, there were drawbacks in terms of lack of O donation from the ligand,
since the O donor increases the stability of the scaffold.25-31 These trinitrogen donor
ligands are widely used in the synthesis of biometallic complexes due to their similar
reactivities to the cyclopentadienyl (Cp) family of ligands, especially when bound to
iron.32 No previous reports using Tp-type ligands as DNA coordination mimics exist, but
it is believed these ligands can be used to mimic metal binding to adenine and guanine
N7, known sites of metal localization (Figure 1.2).33

NH

O

O

N

N

NH

FeII
Z

X
Y

Figure 1.3. Model of the 2-His-1-carboxylate functionality using non-heme iron(II); X,
Y, and Z represent open coordination sites.
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Figure 1.4. Structures of tris(pyrazolyl)borate (TpR) and tris(pyrazolyl)methane (TpmR)
ligands.

A useful property of the N,N,N-type ligands is the ability to tune both their
electronic properties, by using a neutral ligand (TpmR) or negatively-charged ligand
(TpR), and to tune their steric properties by adding the desired R substituents to control
steric bulk. This ability has led to widespread applications of TpR and TpmR ligands in
metalloenzyme model chemistry,29 polymerization catalysis,34 C-H bond activation,35 and
metal ion extraction.36 There also is intrinsic interest in the electronic characteristics of
TpR and TpmR ligands relative to those of other facially-coordinating, six-electron donors
such as 1,4,7-triazacyclononane (TACN) and cyclopentadienyl (Cp) ligands.37,38

Tp-Type Iron Chemistry and Its Applications
Tp-type iron complexes have been extensively studied since they were first
synthesized by Trofimenko in 1966.39

One of these types of complexes are the

octahedral Tp2Fe (1) and Tp*2Fe (2; Figure 1.5) that can be formed in high yields using
iron(II) salts such as FeCl2, Fe(OAc)2, and Fe(OTf)2 with two equivalents of the desired
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TpR ligand. These iron(II) complexes have displayed unusual temperature-dependent
spin-state crossover behavior.40-45
Another type of complex includes oxo-bridged diiron centers, such as Tp2Fe2(µO)(µ-O2CCH3), (3; Figure 1.5) that resembles metalloenzymes such as hemerythrin,
rubrerythrin, and methane momo-oxygenase.

The crystal structure of 3 shows iron

coordination by one µ-oxo and two µ-carboxylato bridges with the Tp ligand mimicking
three histidine moities.46 The five-coordinate iron(III) complex TpiPrFe(OAc) (4; Figure
6) was also synthesized and acts as a mimic for non-heme metalloprotein hemoglobin and
cytochrome P-450.47 Facially-capped Tp-type iron complexes are also of interest as
synthons for magnetic materials. Iron(III) complexes of the type (R = H, Me, iPr; 5;
Figure 1.6) have been synthesized and studied for their electrical and optical properties,
but mostly for their ability to self-assemble into bridged chains that have exhibited
unusual magnetic properties.48,49
Tris(pyrazolyl)methane iron complexes have also been studied since they were
first

synthesized

by

Trofimenko,50

but

not

as

extensively

as

analogous

tris(pyrazolyl)borate iron complexes. Iron complexes of Tpm such as [Tpm2Fe][X2] (X =
BF4-, ClO4-, OTf-; 6; Figure 1.7) can be formed in high yields using iron(II) salts such as
Fe(BF4)2, Fe(ClO4)2, and Fe(OTf)2 with two equivalents of the desired Tpm ligand.
These iron(II) complexes have also displayed unusual temperature-dependent spin-state
crossover behavior similar to that of their Tp2Fe analogs.51
Similarly, Tpm-type iron complexes of considerable interest are the faciallycapped synthons. One example are the complex [Tpm*Fe(NCE)2(NCCH3)] (E = S, Se;
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9; Figure 1.8) which were studied for spin-crossover behavior and found to be
comparable

to

that

of

their

bis-Tpm

analogs.52

Another

complex,

[Tpm*Fe(NCCH3)3][(BF4)2] (10; Figure 1.8), was synthesized and tested to determine if
it could generate a nine-membered triphosphorous macrocycle via intramolecular
hydrophosphination. The complex was treated with bidentate phosphines such as 1,2diphosphinoethane in tetrahydrofuran (THF), and was found to undergo ligand
disproportionation to form [Tpm*2Fe][(BF4)2] and the tris-diphosphino iron(II) species
(Scheme 1).32

Tp-Type Ruthenium Chemistry and Its Applications
Ruthenium is in the same group as iron, but it is a soft, inert metal unlike
borderline, labile iron(II). Ruthenium(II) is diamagnetic, unlike its paramagnetic iron(II)
cousin, making NMR data evaluation of ruthenium(II) complexes more tractable
compared to iron(II). These properties make ruthenium(II) ideal for coordination studies
related to iron(II).
Tp-type ruthenium(II) complexes also have practical uses outside of being
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suitable substitutes for iron(II) such catalysis applications, but they have mostly been
limited to the parent Tp ligand. One example is Tp2Ru (analogous to the iron complex in
Figure

1.5),

synthesized

by

combining

the

thallium

salt

of

Tp

with

tetrakis(benzonitrile)dichlororuthenium(II) in benzene and heating to reflux for two days
before column chromatographic purification. The bis-Tp complex was used as in the
catalytic hydrogenation of olefins such as methyl acrylate.53 Surprisingly, this complex is
the only reported bis-Tp ruthenium complex of any kind.
Another more widely used complex is TpRuCl(COD) (COD = cyclooctadiene; 9;
Figure 1.9), synthesized by heating the polymeric [RuCl2(COD)]n with KTp to reflux in
THF.54

This Tp-type COD-containing complex has been used as a catalyst in the

reactions of phenylacetylene with allyl alcohols to form selective C-O coupled products55
and trimethylsilylacetylene with allyl alcohols to form an (allyloxy)carbenes.56 Another
ruthenium complex, TpRu(R)(NCCH3)Me (R = CO, PMe3; 10; Figure 1.9), activates C-H
bonds in the presence of furan or thiophene to produce methane and TpRu(NCCH3)(aryl)
(aryl = 2 furyl or 2-thienyl)57 and to activate sp3 C-H bonds to form new C-C and C-N
bonds when heated in excess acetone or acetonitrile, respectively.58 Tp*RuH(COD) (11;
Figure 1.9) was generated from RuHCl(COD)(Bpm) (Bpm = bis(pyrazolyl)methane) and
KTp* in hopes of producing a saturating species that could activate C-H bonds or
perform hydrogen transfer reactions.59
The Tp-type ruthenium complexes of the formula [TpRRu(NCCH3)3][X] (R = H,
Me, iPr; X = PF6-, OTf-) are of great interest, since these would make excellent synthons
for a variety of ruthenium chemistry.

[TpRu(NCCH3)3][PF6] (12; Figure 1.10) was

10

synthesized by heating TpRuCl(COD) and NH4PF6 in a 1:1 mixture of dichloromethane
and dimethylformamide to reflux and was originally used to study ligand exchange
kinetics of its acetonitrile ligands in comparison to the analogous [CpRu(NCCH3)3]+.60
[Tp*Ru(NCCH3)3][OTf] (13; Figure 1.10) was prepared by stirring Tp*RuH(H2)2 with
triflic acid at -80 °C in THF, and was created as a byproduct when determining the
strength of acid needed to create H2 gas from the Ru(II) starting material.61
[TpiPrRu(NCCH3)3][OTf]

(14;

Figure

1.10)

was

synthesized

by

stirring

[TpiPrRu(OH2)2(THF)][(OTf)(THF)2] in acetonitrile.62
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Figure 1.9. Structures of TpRuCl(COD) (9, top), TpRu(R)(NCCH3)Me (R = CO,
P(CH3)3; 10, middle), and Tp*RuH(COD) (11, bottom).
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Figure 1.10. Structures of [TpRRu(NCCH3)3][X] (R = H, X = PF6-, 12; R = Me, X =
OTf-, 13; R = iPr, X = OTf-, 14).

Unlike Tp-type ruthenium complexes, reports of Tpm-type ruthenium complexes
are rare. One complex, fac-[TpmRu(DMSO-S)2(DMSO-O)][(OTf)2] (15; Figure 1.11),
was made by heating fac-[Ru(DMSO-O)3(DMSO-S)3][(OTf)2] with Tpm in methanol to
reflux. But unlike its Tp-type ruthenium analogs, only two of the three pyrazole rings
coordinate to the metal center, as proven through X-ray crystallography.63 Another
reported complex, [TpmRu(OH2)3][(OTs)2] (16; Figure 1.11), was synthesized by
cleaving the diruthenium species Tpm2Ru2(OH)(µ-O)(µ-O2PO) with tosylic acid in an
aqueous solution in hopes to form dioxygen through electrooxidation of the ruthenium
center.64
The most relevant Tpm-type ruthenium(II) complex pertaining to this work is
[TpmRuCl(NCCH3)2][PF6] (17; Figure 1.12).

It is believed that with two weakly-

coordinated acetonitrile solvato ligands, this complex would be a valuable synthon to
perform subsequent ruthenium chemistry.

This Tpm-ruthenium(II) complex was

synthesized by heating the ruthenium(III) species TpmRuCl3 to reflux with Zn dust in
acetonitrile, followed by a counterion exchange with NH4PF6.65
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No reports exist for the synthesis of bis-Tpm ruthenium(II) complexes. The
closest structure to a true bis-Tpm ruthenium(II) complex, where all six coordination site
are occupied by two Tpm ligands, is [Tpm2RuCl][Cl] (18; Figure 1.12), made by
combining a solution of the ruthenium(III) species TpmRuCl3 and LiCl in water and a
solution of Tpm and triethylamine in ethanol and heating to reflux. As proven by 1H and
13

C NMR spectroscopy, only five of the six pyrazole rings are bound to the metal center.

Upon removing the chloride with AgClO4 and heating the reaction mixture in acetonitrile
to reflux to allow for the sixth ring to bind, 1H and 13C NMR spectroscopy showed that
the metal center exchanged the chloride for an acetonitrile ligand instead of binding the
sixth nitrogen of the Tpm ligand (19; Scheme 1.2).66

Biological Applications of Ruthenium
Although ruthenium is not an essential metal, ruthenium complexes are also of
biological interest in cancer treatment. Since the discovery of cisplatin-resistant forms of
cancer, research has been conducted to discover other transition metal-based
chemotherapeutic drugs to help combat more aggressive cancer cell lines.67 One of these
ruthenium drugs is trans-[HIm]-[RuIIICl4(DMSO)(Im)] (NAMI-A, or new anti-tumor
metathesis inhibitor-A; 20; Figure 1.13).68 Unlike other ruthenium-based complexes,
NAMI-A has the ability to eradicate tumor metastases.69 This property may be due to the
ability of NAMI-A and other Ru(III) complexes with similar structures70 to be
transported by vacant Fe(II) sites in transferrin and lactoferrin to distant cancer cells.69,71
Once these complexes reach target cancer cells, they then interact with either
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extracellular matrix components72 or some form of cellular receptor68 to enter the cell via
endocytosis.67 Upon entering the cancerous cell, it is currently believed that the Ru(III)
center is then reduced to Ru(II) by glutathione.73 Finally, the complex binds to the target
cell’s DNA via guanine, causing DNA crosslinks and inhibiting the function of
topoisomerase II.74
One study of particular interest is the use of ruthenium(II) arene complexes of the
type [(η6-arene)Ru(X)(Y)(Z)] (arene = substituted benzene; X, Y, Z = halides,
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Figure 1.13. Structure of NAMI-A (20).

acetonitrile, isonicotinamide; 21; Figure 1.14), that were synthesized and tested in A2780
(ovarian) cancer cell growth inhibition assays. These ruthenium(II) complexes inhibited
cell growth similarly to that of carboplatin (22; Figure 1.14), and 1H NMR spectroscopy
indicated that the metal center was strongly bound to the guanine N7 in DNA.76

This

reinforces the proposal that ruthenium(II) may be a useful mimic for iron(II) in biological
studies.

It also shows ruthenium complexes of Tp-type ligands may be useful for

studying metal-ion interactions with DNA.
An example of Tp-type ruthenium complexes that are of biological interest is the
aforementioned [TpmRuCl(NCCH3)2][PF6] (17; Figure 1.12).

This complex was

originally made as a starting material so that bidentate phosphine ligands could be added.
The resulting complex was tested in vitro against breast (MCF-7) and cervical (HeLa)
cancer cell lines. Complex 17 has shown significant cytotoxicity based on 3-(4,5-
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Figure 1.14. Structures of [(η6-arene)Ru(X)(Y)(Z)] (21, left), and carboplatin (22, right).

dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assays,65 a colorimetric
assay used to measure enzyme activity that can be used the assess the viability and
proliferation of cells.75 Due to structural similarities of 17 with the arene complex 21, it
is likely this complex may also bind DNA to exert its anticancer effects.
This review shows Tp-type iron(II) and ruthenium(II) complexes have uses in
catalysis, as biomimetics, and in biological studies. It also shows that this class of
complexes has the potential to be used in biologically-relevant studies of DNA. The
research presented in Chapter 2 describes the synthesis and characterization of
tris(pyrazolyl)borate and tris(pyrazolyl)methane complexes of iron(II), with an emphasis
on electrochemical studies.

Novel iron(II) complexes containing chalcogenates and

chalcogenones were also synthesized and the studies conducted on these complexes show
the effects sulfur and selenium have on the electrochemical behavior of iron(II). These
studies help us understand how changing the electrochemical behavior of iron(II) affects
its ability to undergo the Fenton reaction.
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An improved synthetic method for the synthesis of tris(pyrazolyl)borate
ruthenium(II) complexes as well as the synthesis and characterization of novel
tris(pyrazolyl)methane complexes of ruthenium(II) are presented in Chapter 3.

The

improved syntheses of these Tp-type complexes also yields a quick and effective pathway
for making ruthenium(II) synthons to use in catalysis or as building blocks for subsequent
synthetic chemistry. Cyclic voltammetry studies conducted on these species show how
the coordination of Tp-type ligands alters the electrochemical behavior of ruthenium(II).
These electrochemical studies show that the coordination of N,N,N-type donors such as
Tp also affect the redox chemistry of ruthenium.
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CHAPTER TWO
SYNTHESIS AND CHARACTERIZATION OF IRON(II) COMPLEXES
CONTAINING TRIS(PYRAZOLYL) LIGANDS AS WELL AS SULFUR- OR
SELENIUM-CONTAINING LIGANDS AND THEIR BIOLOGICAL RELEVANCE

Introduction
In cells, unbound iron(II) is prone to electron transfer reactions that enable it to
generate hydroxyl radical (OH) in the Fenton reaction (Reaction 1).1 The generated
hydroxyl radical can cause oxidative stress in cells and damage to DNA.2 Hydroxyl
radical is an underlying cause of chronic or degenerative diseases and is also a primary
factor in the aging process.3-10 Therefore it is of great interest to investigate methods to
prevent hydroxyl radical formation for disease prevention and treatment.

Fe2+ + H2O2

Fe3+ + .OH + OH-

(1)

Selenium is a required dietary micronutrient for most animals,1,5 and selenium
compounds have also been reported as vital antioxidants,11,12 protecting and
strengthening the immune system by preventing radical formation. World population
studies show that where the soil is rich in selenium, there are significantly lower levels of
cancers.13

The Nutritional Prevention of Cancer (NPC) trial found that a regular

supplement of dietary selenium in humans (200 µg/day) can reduce the occurrence of
prostate cancer by 63%, colorectal cancer by 58%, carcinoma by 45%, and lung cancer
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by 48% over a ten year period,14 though a larger study of selenium and vitamin E
supplementation on prostate cancer, the SELECT trial, found that selenium
supplementation using yeast enriched with primarily L-selenomethionine (200 µg/day;
SeMet; Figure 2.1) was not as effective in preventing prostate cancer as once thought.15
Many population studies have also shown that selenium is a protective nutrient against
the development of heart and artery disease.16

These findings have led to the

development of organoselenium drugs, which are less toxic than inorganic selenium and
appear to be bioavailable.6,7 In Japanese clinical trials, the selenium-containing drug
ebselen was found effective for treatment of stroke, and 1,2–diselenone-3-pentanoic acid,
the selenium analog of α-lipoic acid, is a well-studied naturally-occurring antioxidant.17
Selenium

can

be

found

as

selenocysteine

(SeCys;

Figure

2.1)

and

selenomethionine (Figure 2.1) in plants, which naturally replace sulfur in cysteine and
methionine with selenium absorbed from the soil.18 Selenocysteine is also specifically
incorporated into the active sites of antioxidant proteins such as glutathione peroxidase
(GPx),17 thioredoxin reductase,19 and selenoproteins P, W, and R.20
Selenolates (RSe-) in biological systems coordinate metal ions similarly to
thiolates (RS-). Iron thiolate complexes can mimic ferridoxins (Figure 2.2), iron-sulfur
proteins that are involved in the transfer of electrons in metabolic processes, such as
those found in the mitochondria of anaerobic bacteria21 and the chloroplasts of plants.22
Another example of iron thiolate complexes is the family of rubredoxins (Figure 2.2),
iron-sulfur proteins that are also involved in electron transfer reactions and found
exclusively in sulfur-processing archaebacteria.23 Selenolate-metal coordination is
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Figure 2.1. Structures of sulfur-containing amino acids tested for antioxidant activity.

found in the [NiFeSe] hydrogenases, a group of metalloenzymes also found in sulfurprocessing archaebacteria that catalyze the hydrolysis of hydrogen gas into hydrogen ions
and electrons. They are generally heterodimeric, contain three iron–sulfur clusters in
their small subunit and a nickel-iron-containing active site in their large subunit that
incorporates a SeCys residue bound to nickel(II).24
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Figure 2.2. Structures for the Fe-S clusters in ferredoxin (a) and rubredoxin (b).

The heterocyclic chalcogenone ergothioneine (Figure 2.3), widely found in
actinobacteria, is an amino acid that is a thiourea derivative of histidine.25 Its selenium
analog, selenoneine (Figure 2.3), mostly found in fish such as bluefin tuna (430 nmol/g),
is a major dietary source of selenium for largely fish eating cultures.26

These

chalcogenones resemble methimazole, a drug currently used in the treatment of
hyperthyroidism.27 Heterocyclic chalcogenones such as those shown in Figure 2.3 also
coordinate iron(II) well, since they are σ- and π-donors as well as π-acceptors. Raper,28
Akrivos,29 Spicer et al.,30 and Pettinari31 have previously reviewed the coordination
chemistry of selones and thiones with transition metals and halogens.
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Small-molecule sulfur and selenium antioxidants help prevent or minimize
widespread cellular damage from reactive oxygen species including OH. Studies by
Battin et al. have shown using gel electrophoresis DNA damage assays that the sulfurcontaining cellular antioxidants reduced glutathione (GSH) and oxidized glutathione
(GSSG; Figure 2.1) inhibit iron-mediated DNA damage. GSH inhibited iron-mediated
DNA damage (23.0 ± 8.4% inhibition at 10,000 µM) at a concentration well within
biological concentrations (up to 15,000 µM in the nucleus). GSSG also inhibited ironmediated DNA damage (50.2 ± 4.5% inhibition at 10,000 µM), giving credence as to why
glutathione is the primary sulfur-containing cellular antioxidant. In contrast, the sulfurcontaining amino acids cysteine (Cys), cystine (Cys2), and methionine (Met; Figure 2.1)
do not effectively inhibit iron-mediated DNA damage. It was determined that metal
coordination is required for the majority of glutathione antioxidant activity, as determined
by similar studies conducted with chelated iron (in the form of [Fe(EDTA)]2-) using gel
electrophoresis.32

28

Selenium concentrations in biological systems are small,33 so it is believed that no
more than one selenium-containing ligand would typically be involved in biological
metal coordination. Battin et al. also used DNA damage assays to study the ability of
selenium-containing compounds found in biological systems to inhibit iron-mediated
DNA damage.

Of the 12 selenium compounds studied, only methyl-selenocysteine

(MeSeCys; Figure 2.4; IC50 of 378.4 ± 0.1 µM) and selenocystamine (SeCysta; Figure
2.4; IC50 of 121.4 ± 0.3 µM) inhibited iron-mediated DNA damage, although these
concentrations are much higher than biological selenium concentrations.

It was

determined, as for the previously tested sulfur-containing compounds, that iron
coordination is required for the majority of this antioxidant activity.34
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selenocystamine (SeCysta)

Figure 2.4. Structures of selenium-containing amino acids tested for antioxidant activity.
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Based on these data, synthesis and electrochemical study of biologically-relevant
Tp-type iron(II) complexes (Figure 2.5) containing chalcogenates and chalcogenone
ligands may help understand how changing the electrochemical behavior of iron(II)
affects its ability to undergo the Fenton reaction. In the attempts to synthesize these
complexes, two different methods are employed. One method entailed the chelation of
iron(II) with Tp-type ligands to form Tp-type iron(II) complexes with labile solvato
ligands, such as acetonitrile. Labile solvato ligands were used so that they can be
replaced with sulfur- or selenium-containing ligands in subsequent steps. This reaction
was followed by addition of the chalcogenate or chalcogenone ligands. The second
method involved initial coordination of the chalcogenate or chalcogenone ligands to form
iron(II)-sulfur and -selenium complexes, followed by chelation of the Tp-type ligand.
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Figure 2.5. Target iron(II) complexes.
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Results and Discussion
Synthesis

of

Tp-type

iron(II)

tris(acetonitrile)

complexes.

[Tp*Fe(NCCH3)3][BPh4] (1) was synthesized by slow cannula addition of the potassium
salt of Tp* (Tp, R = Me) in acetonitrile to iron(II) triflate in acetonitrile. Immediately, a
light pink solution formed and potassium triflate (KOTf) precipitated as a white solid.
After separating the KOTf by cannula filtration, NaBPh4 was added to the solution to
perform a counteranion exchange, and the mixture was stirred overnight to yield a red
solution.

The volume of the solvent was reduced, and diethyl ether was added to

precipitate a white solid (Figure 2.6). The 1H NMR spectrum for 1 is quite similar to that
reported for its Fe-Tpm* analog.35 The BH proton appears as a broad singlet at δ -12, the
two methyl groups at δ 39 and δ 14, and the 4-H of the pyrazole appears at δ 58. A sharp
peak at δ -79 in 19F{1H} NMR indicates the presence of uncoordinated triflate ion.

H
B
Fe(OTf)2 . 2 CH3CN +

N
N

N

BPh4

H
B

K

N

CH3CN

N

NaBPh4

N

N

N

N

N

N

N

+ 2 NaOTf + KOTf

Fe
H3CCN

NCCH3
NCCH3

Figure 2.6. Synthesis of [Tp*Fe(NCCH3)3][BPh4] (1); yield 65%.

The IR spectrum of the free Tp* ligand shows a B-H stretching vibration at 2470
cm-1, and the bound acetonitrile on iron(II) triflate of the form Fe(OTf)2(NCCH3)2 has a
nitrile stretching vibration at 2292 cm-1. Upon Tp* coordination to iron(II) triflate, the B-

31

H stretch shifts to 2924 cm-1, a significantly higher energy relative to the unbound ligand,
indicative of strong donor bonding to iron. The nitrile stretch from the iron-bound
acetonitrile ligands shifts to 2319 cm-1, a higher energy, indicating stronger donor bonds
between iron and acetonitrile upon addition of both Tp* and an acetonitrile solvato
ligand.
[Tpm*Fe(NCCH3)3][(BPh4)2] (2) was synthesized similarly to a reported
procedure (Tpm* = Tpm, R = Me;35 Figure 2.7). The 1H NMR spectrum shows a broad
resonance at δ -42.2, characteristic of the apical CH proton. Broad resonances at δ 54 (4H on the pyrazole ring), 35 (3-methyl), and 12.7 (5-methyl) are due to Tpm* coordination
to the metal ion. The

19

F{1H} NMR spectra shows a singlet at -79 ppm, indicating the

presence of uncoordinated triflate anion.

N
Fe(OTf)2 . 2 CH3CN +
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N
N
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2 NaBPh4

N

N

N

N

N

N

+ 2 NaOTf

Fe
NCCH3

H3CCN

NCCH3

Figure 2.7. Synthesis of [Tpm*Fe(NCCH3)3][(BPh4)2] (2), yield 43%.

Attempts to coordinate sulfur- and selenium-containing ligands using sodium
phenylthiolate (NaSPh), sodium phenylselenolate (NaSePh), 1,3-dimethylimidazole-2thione

(DImT),

and

1,3-dimethylimidazole-2-selone
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(DImSe;

Figure

2.8)

to

tris(acetonitrile) complexes 1 and 2 afforded products that could not be separated from
the reaction mixture, as determined from paramagnetic 1H NMR spectra.
Synthesis of iron(II) sulfur and selenium compounds. Since sulfur- and seleniumcontaining ligands do not provide clean products with Tp-type iron(II) complexes,
Fe(EPh)42- complexes (E = S, Se; Figure 2.9) were synthesized to attempt to synthesize
the target iron(II) complexes. This approach differs as it involves coordinating the
chalcogen to the metal before addition of the Tp-type ligand.

E
E Na

N

N

sodium phenylthiolate (NaSPh), E = S
1,3-dimethylimidazole-2-thione, E = S
sodium phenylselenolate (NaSePh), E = Se 1,3-dimethylimidazole-2-selone, E = Se

Figure 2.8. Sulfur- and selenium-containing compounds used in this work.

The iron(II) selenolate complex (3) was prepared as previously reported,36 but
was modified to prepare the iron(II) thiolate complex (4). Addition of hydrated iron(II)
chloride to sodium phenylthiolate yielded a dark purple solution and purple crystals of 4
upon cooling overnight. Comparison of the paramagnetic 1H NMR spectra of 3 and 4 to
the reported values for the phenylselenolate complex suggest that the protons of the
ortho, meta, and para positions from the phenylselenolate ligands are reversed from what
was reported. Specifically, the resonances for the ortho and para protons have a positive
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chemical shift (δ 18 and 16, respectively, compared to δ -16 and -18 reported) and the
meta proton has a negative chemical shift (δ -16.5 compared to the reported δ 16).

.

2 PPh4

E
FeCl2 . 4 H2O + 4 NaEPh

2 PPh4Cl

Fe
E

THF

+ 4 NaCl
E

E

(3) E = Se
(4) E = S

Figure 2.9. Preparation of [Fe(SePh)4][(PPh4)2]36 (3) and [Fe(SPh)4][(PPh4)2] (4).

To compare iron(II) complexes with different sulfur- and selenium-containing
ligands, [Fe(DImE)2][(OTf)2] compounds were synthesized, where E is again sulfur (5)
or selenium (6; Figure 2.10). Paramagnetic 1H NMR spectra of 5 shows a downfield shift
from δ 3.5 (N-Me) and δ 6 (olefinic) for the free thione to δ 11 and δ 10, respectively, for
the bound thione ligand. The spectra also show two resonances each for the methyl and
olefinic protons, suggesting that the protons of the imidazole ligands have different
environments. This same phenomenon is seen in the 1H NMR spectrum of 6.
The IR spectrum of the free thione shows a C=S stretching vibration at 1181 cm-1,
whereas the free selone has a C=Se stretching vibration at ~1148 cm-1, consistent with
previous reports for DImT, 1,1'-methylenebis(1,3-dihydro-3-methyl-2H-imidazole-2-
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CH3OH
N

E

N
N

Fe

E

OTf

N
N

(5) E = S
(6) E = Se

Figure 2.10. Synthesis of [Fe(DImT)2][(OTf)2] (5) and [Fe(DImSe)2][(OTf)2] (6).

thione) (Mbit), and 1,1'-methylene-bis(1,3-dihydro-3-methyl-2H-imidazole-2-selone)
(Mbis).37-39 Upon DImT coordination to iron(II) triflate, the C=S stretch shifts to 1174
cm-1, a lower energy relative to the unbound ligand indicative of weak iron backbonding
to the thione ligand. Coordination of DImSe to iron(II) triflate results in a shift of the
C=Se stretch to 1155 cm-1, a slightly higher energy, indicating that iron backbonding
interactions with this ligand are not significant.

A similar difference in vibrational

energies is seen for DImT and DImSe binding to copper(I).40
Attempts at coordinating Tp* and Tpm* to both types of sulfur- and seleniumcontaining complexes yield a variety of results. Paramagnetic 1H NMR spectra indicate
that addition of Tp* and Tpm* to complexes 3 – 6 yielded results ranging from no
reaction to ligand disproportionation upon addition of TpR ligands (Figure 2.11).
A comparison of the electrochemistry of iron(II) complexes. Cyclic voltammetry
was performed on the new iron(II) complexes to understand how coordination of both
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Figure 2.11. Results of adding Tp-type ligands to the synthesized iron(II) sulfur- and
selenium-containing complexes. All reactions were performed in acetonitrile.

Tp-type ligands and sulfur- and selenium-containing ligands to iron(II) affects its redox
chemistry. Changing the redox chemistry may affect the ability of iron(II) to generate
hydroxyl radical in the Fenton reaction.
Upon comparing the measured Fe2+/Fe3+ potentials (Table 2.1) of the Tpcontaining iron complexes with the sulfur- and selenium-containing iron complexes, it is
clear that addition of a single Tp-type ligand to iron(II) triflate generally results in more
positive Fe2+/3+ potentials. These potentials indicate that iron(II) is less stable relative to
iron(III). On the other hand, the addition of sulfur- and selenium-containing ligands to
iron(II) triflate yields negative potentials, indicating that sulfur and selenium coordination
stabilizes iron(II) relative to iron(III).
The potentials in Table 2.1 show that the addition of multiple Tp* ligands to iron
result in lower Fe2+/3+ potentials. For example, the bis Tp-type analog, Tp*2Fe, has a
more negative reversible Fe2+/3+ potential of 0.241 V vs. normalized hydrogen electrode
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Table 2.1: Fe2+/3+ potentials for target complexes (E vs. NHE).
Complex

Epa (V)

Epc (V) E½, Fe2+/3+ (V)

Ref.

Fe(OTf)2(NCCH3)2

0.633

0.913

0.771

This work

Tp*2Fe

0.189

0.294

0.241

41

[Tpm*2Fe][(OTf)2]

0.916

1.02

0.968

41

[Tp*Fe(NCCH3)3][BPh4] (1)

0.698

0.850

0.776

41

[Tpm*Fe(NCCH3)3][(BPh4)2] (2)

0.879

1.04

0.761

41

[Fe(SPh)4][(PPh4)2] (3)

-0.650

-0.796

-0.723

This work

[Fe(SePh)4][(PPh4)2] (4)

-1.07

-0.942

-1.01

This work

[Fe(DImT)2][(OTf)2] (5)

-1.31

-0.176

-0.547

This work

[Fe(DImSe)2][(OTf)2] (6)

-0.401

-0.047

-0.047

This work

(NHE) than both the mono Tp-type analog 1 (0.776 V) and iron(II) triflate (0.771 V).
The potentials show that the coordination of multiple Tp* ligands stabilizes iron(III)
relative to iron(II) better than does a single Tp* ligand due to the negative charge of the
Tp* ligand.
Conversely, the potentials in Table 2.1 show that addition of multiple neutral
Tpm* ligands to iron yields a more positive potential than having one neutral Tpm*
ligand coordinated to iron(II). The Tpm analog, [Tpm*2Fe][(OTf)2], has a more positive
reversible Fe2+/3+ potential of 0.968 V vs. NHE than that of the mono Tpm analog 2
(0.761 V). Also note that 2 has a slightly lower potential than iron(II) triflate (0.771 V).
This trend can be explained due to the presence of the acetonitrile solvato ligands. Recall
that the IR spectrum of iron(II) triflate of the form Fe(OTf)2(NCCH3)2 has a nitrile
stretching vibration for its bound acetonitriles at 2292 cm-1.
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The nitrile stretching

vibration for 2 is shifted to a lower energy, 2283 cm-1, upon addition of both Tpm* and
an additional acetonitrile. The coordinated nitrogens of acetonitrile have the ability to σdonate and π-accept when bound to a metal center, resulting in backbonding of its d
orbitals to the empty π* orbital of the acetonitrile nitrogens, which is indicated by the
lower vibrational energy. Thus, since [Tpm*Fe(NCCH3)3][(BPh4)2] (2) gains one solvato
ligand, it yields the slightly lower potential regardless of Tpm* coordination; the bis
analog has no solvato ligands from which it can backbond compared to 2, thus the higher
potential. Thus the addition of multiple neutral Tpm* ligands better stabilizes iron(II)
relative to iron(III) than does adding one Tpm* ligand.
However, the previous trend only holds true if more than one charged N,N,N-type
donor is added to the metal center.

[Tp*Fe(NCCH3)3][BPh4] (1; 0.776 V) has a

reversible Fe2+/3+ potential that only differs by 15 mV as compared to complex 2 (0.761
V).

But when more than one trinitrogen donor is added, the difference in potential

widens greatly between Tp*2Fe and [Tpm*2Fe][(OTf)2] (727 mV). The potentials again
show that the addition of charged species results in the stabilization of iron(II) over
iron(III). The potentials also show that the charge of the trinitrogen donor has minimal
effect on potential when only one ligand is coordinated to the metal center.
Comparing the Fe2+/3+ potentials for the iron chalcogenate complexes, it can be
seen that selenolate coordination of 4 (-1.01 V) negatively shifts the potential of the
iron(II) compared to its thiolate analog, 3 (-0.723 V). This is because the selenolate is a
softer base than the thiolate, meaning that the selenolate has more polarizable valence
electrons than the thiolate. Although iron(II) is a borderline acid, the softer selenolate
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will donate its pair of electrons through σ-donation more effectively than the thiolate,
more effectively stabilizing iron(II) over iron(III).
In contrast, comparing the electrochemical potentials of complexes 5 and 6 show
that the thione (-0.547 V) has a more negative potential than the selone (-0.047 V). The
results can be explained using previously-discussed IR data for 5 and 6. Recall that the
C=S stretch for 5 shifts to a lower energy relative to the unbound thione ligand, whereas
the C=Se for 6 shifts to a slightly higher energy compared to unbound selone. Thus,
backbonding to the thione ligand is more significant than to the selone ligand, indicating
that the electrons from the thione ligand are not as readily donated to the iron center than
with the selone ligand. These data show that both the thione and selone stabilize the
iron(II) metal center relative to iron(III), but the selone is more effective at stabilizing the
iron(II) center than the thione.
Biological implications of this work. The biological Fenton reaction occurs only
over a specific electrochemical range (-0.324 V to 0.460 V).42 To illustrate the biological
implications of the potentials in Table 2.1, Figure 2.13 shows the potentials of the iron
complexes relative to the electrochemical window in which the Fenton reaction can
occur.

Previous reports have shown that complexation of iron(II) alters its

electrochemical properties compared to iron(II).18

Based on the electrochemical

potentials for the iron(II) complexes, chelation of either the DNA mimic Tp-type ligands
or sulfur and selenium may inhibit the Fenton reaction. Tp-type coordination to iron(II)
may stabilize iron(II) to H2O2 oxidation, whereas sulfur and selenium coordination may
stabilize iron(III) to NADH reduction, preventing iron redox cycling. These findings are
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consistent with the findings of Battin et al., where coordination of selected sulfur- and
selenium-containing compounds is a mechanism for preventing iron-mediated DNA
damage.32,34

Figure 2.12. Depiction of where the potentials of iron(II) complexes lie in relation to the
electrochemical window for the biological Fenton reaction.

Based on the findings presented in this chapter, it can be concluded that
coordination of ligands to iron can significantly alter its electrochemical behavior. The
ability to stabilize either oxidation state of iron (+2 or +3) is important not only to
biological systems, but could also be used to tune the reactivity of iron complexes for use
in catalysis.
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Experimental Methods
General air-sensitive techniques under argon were used to synthesize the
complexes unless otherwise stated. 1H and 19F{1H} NMR spectra were obtained using a
Bruker-AVANCE NMR spectrometer at 300 MHz. 1H NMR chemical shifts are reported
in δ relative to tetramethylsilane (TMS) and referenced to solvent. 19F{1H} NMR spectra
were externally referenced to CCl3F (δ 0).43 Infrared spectra were obtained using Nujol
mulls on KBr salt plates with a Magna 550 IR spectrometer. Abbreviations used in the
description of vibrational data are as follows: vs, very strong; s, strong; m, medium; w,
weak; b, broad. Electrospray ionization mass spectrometry (ESI-MS) was conducted
using a QSTAR XL Hybrid MS/MS System from Applied Biosystems via direct injection
of sample (0.05 mL/min flow rate) into a Turbo Ionspray ionization source. Samples
were run under positive mode in methanol, with ionspray voltage of 5500 V, and in TOF
scan mode. Peak envelopes match theoretical calculations for their ions. Elemental
analyses were performed in-house on a Perkin Elmer 2400 Series II CHNS/O Elemental
analyzer.
Methyl iodide, potassium borohydride, 3,5-dimethylpyrazole, precipitated sulfur,
sulfur powder, and tetra-n-butylammonium bromide were purchased from Alfa Aesar;
sodium hydride, diethyl ether, hydrated iron(II) chloride, diphenyl diselenide, and iron
powder were purchased from Fisher/Acros; methanol, and acetonitrile were purchased
from Mallinkrodt; chloroform and sodium sulfate were purchased from BDH; sodium
tetraphenylborate was purchased from Lancaster; dry methanol was purchased from
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Burdick; and diphenyl disulfide, 1-methylimidazole, and tetraphenylphosphonium
chloride were purchased from TCI.
Iron(II) triflate,44 KTp*,45 Tpm*,46 sodium phenylselenolate (NaSePh),47,48
sodium

phenylthiolate

(NaSPh),47,48

1,3-dimethylimidazole-2-thione,49

1,3-

dimethylimidazole-2-selone,49 and [Fe(SePh)4][(PPh4)2]36 were synthesized using
reported procedures.

[Tpm*Fe(NCCH3)3][(BPh4)2] was synthesized according to the

procedure reported for synthesizing [(Tpm*)Fe(NCCH3)3][(BF4)2].35
Synthesis of [Tp*Fe(NCCH3)3][BPh4], 3. The potassium salt of Tp* (1) (0.168 g,
0.5 mmol) dissolved in acetonitrile (10 mL) was added dropwise using a cannula to a
solution of Fe(OTf)2

.

2 CH3CN (0.5 mmol, 0.22 g) in acetonitrile (10 mL), and the

solution was stirred for 30 min. A white precipitate formed and the solution turned
gradually to a pale pinkish-red color. The white solid was separated using cannula
filtration, and a solution of NaBPh4 (0.171 g, 0.5 mmol) dissolved in acetonitrile (15 mL)
was added and stirred overnight. The solution was concentrated by reducing the volume
of the solvent to 2 mL, and a dull white solid precipitated. Ether (10 mL) was added to
facilitate precipitation, and the light pink solid was separated by cannula filtration,
washed with ether (2 × 5 mL), and vacuum dried. Total yield: 0.258 g, 65%. 1H NMR
(acetone-d6): δ 59 (3H, 4-H(pz)), 39 (9H, -Me), 14 (9H, -Me), 6.95 (t, -Ph), 6.75 (t, -Ph).
IR (cm-1): 486 w, 596 w, 652 w, 721 m, 847 w, 1030 w, 1152 w, 1304 w, 1543 w, 1578
w, 2265 w, 2326 w, 2360 w, 2665 w, 2730 w.
Synthesis of [Fe(SPh)4][(PPh4)2], 5.

Hydrated iron(II) chloride (1.0 g, 4.27

mmol) in acetonitrile (50 mL) was added dropwise to a stirring solution of sodium
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phenylthiolate (2.31 g, 17.5 mmol) in acetonitrile (30 mL) and the resulting brown
solution was then heated to 60°C for 30 min. Tetraphosphonium chloride (3.36 g, 8.96
mmol) was added and heated for an additional 15 min and filtered. Diethyl ether (40 mL)
was added to the solution to facilitate crystallization, and the solution was stored
overnight at -20°C to afford purplish-brown crystals. Total yield: 4.4 g, 88%. 1H NMR
(DMSO-d6): δ -24 (s, 8H, SPh m-H), 7.37 (s, 8H, PPh o-H), 7.79 (s, 4H, PPh p-H), 7.95
(s, 8H, PPh m-H), 20.5 (s, 8H, SPh p-H), 21.5 (s, 4H, SPh o-H).
Synthesis of Fe(DImT)2(OTf)2, 7. A mixture of 1,3-dimethylimidazole-2-thione
(0.151 g, 1.2 mmol) and iron(II) triflate (0.25 g, 0.6 mmol) was dissolved in methanol (15
mL) and stirred for 12 h, resulting in a yellow solution. The solvent was removed in
vacuo, and the green solid was extracted with dichloromethane (2 × 7 mL) and filtered.
The filtrate was dried in vacuo to yield a bluish-green solid. Total yield: 0.269 g, 74%.
1

H NMR (CD3CN): δ 15.2 (2H, Im-H), 10 (2H, Im-H), 6.2 (3H, Im-Me), 5.9 (6H, Im-

Me).

19

F{1H} NMR (CD3CN): δ -74.5 (s). IR (cm-1): 635 s, 678 w, 757 w, 801 w, 1035

vs, 1091 w, 1174 vs, 1260 vs, 1561 m, 1655 w, 2345 w, 2373 w, 3126 m, 3152 m, 3484
b. Mass spectrum (ESI-MS): m/z 460.9 [Fe(DImT)2(OTf)]+, 318.9 [Fe(DImT)2]+. Anal.
Calc. for FeC12H16S4F6O6N4: C, 19.66; N, 10.49; H, 2.62. Found: C, 18.77; N, 10.91; H,
3.01.
Synthesis of Fe(DImSe)2(OTf)2, 8. A mixture of 1,3-dimethylimidazole-2-selone
(0.208 g, 1.2 mmol) and iron(II) triflate (0.25 g, 0.6 mmol) was dissolved in methanol (20
mL) and stirred for 12 h, resulting in an orange solution. The solvent was removed in
vacuo, extracted with dichloromethane (2 X 7 mL), and filtered. The filtrate was dried in
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vacuo to yield a dark red solid. Total yield: 0.193 g, 46%.

1

H NMR (CD3CN): δ 16.3

(2H, Im-H), 11.2 (2H, Im-H), 6.2 (3H, Im-Me), 5.9 (6H, Im-Me).

19

F{1H} NMR

(CD3CN): δ -75 (s). IR (cm-1): 638 s, 740 w, 798 m, 1029 vs, 1094 m, 1155 s, 1259 vs,
1561 m, 1655 w, 2345 w, 2373 w, 3108 m, 3142 m, 3449 b.

Calc. for

FeC12H16S2F6O6N4Se2: C, 17.04; N, 9.09; H, 2.27. Found: C, 18.07; N, 10.21; H, 2.31.
Electrochemical studies of synthesized iron(II) complexes. Cyclic voltammetry
(CV) experiments were carried out using CHI Electrochemical analyzer and employed a
three-electrode cell consisting of glassy carbon working electrode, a Ag/AgCl reference
electrode, and a platinum wire auxiliary electrode. The glassy carbon electrode was
polished with alumina prior to each trial. CV experiments were conducted in acetonitrile
containing 0.1 mM complex and 0.1 M tetra-n-butyl ammonium hexaflurophosphate
(TBAPF6) at a scan speed of 0.1 V/s from -1.25 V to 1.25 V.

Solutions were

deoxygenated with dry nitrogen gas and maintained under a blanket of nitrogen during
measurements, and voltammograms were referenced to the ferrocene/ferricenium couple
(Fc+/0) at 0.46 V.50 Formal potentials were evaluated as E½ = (Epa+Epc)/2, where Epa and
Epc are anodic and cathodic peak potentials.
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CHAPTER THREE
SYNTHESIS AND CHARACTERIZATION OF RUTHENIUM(II) COMPLEXES
CONTAINING TRIS(PYRAZOLYL) BORATE AND –METHANE LIGANDS

Introduction
Although ruthenium is not a biologically essential metal like iron, ruthenium
complexes are of biological interest. They have been shown to aid in the treatment of the
rejection of cadaver skin grafting,1 autoimmune deficiencies,2 and the kinetic study of
glutathione oxidation.3

It is also of interest in cancer treatment; the discovery of

cisplatin-resistant forms of cancer has lead researchers to investigate transition metalbased chemotherapeutic drugs in addition to platinum drugs that could interact with
DNA, such as the ruthenium-containing compound NAMI-A, to help combat aggressive
cancer cell lines.4,5 The advantage to using ruthenium in this work is that it is in the same
group as iron, but it is a soft, inert metal unlike borderline iron(II). Ruthenium(II) is also
diamagnetic, unlike its paramagnetic iron(II) cousin, making NMR data evaluation more
tractable. These properties make ruthenium(II) ideal for coordination studies related to
iron(II) and can also be a useful substitute for iron(II) in biological studies of DNA
binding.
Ruthenium(II) arene complexes of the type [(η6-arene)Ru(X)(Y)(Z)] (arene =
substituted benzene, X, Y, Z = halides, acetonitrile, isonicotinamide; Figure 3.1) exhibit a
similar inhibition of cell growth to that of carboplatin, an analog of cisplatin (Figure 3.1),
and 1H NMR spectroscopy indicated that the metal center was strongly bound to the
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guanine N7 in DNA.4 The use of capping N,N,N-type ligands, such as the Tp-type
ligands, in ruthenium-based complexes may allow the study of how ruthenium(II)
interacts with DNA. Tp-type ruthenium complexes, such as [TpmRuCl(NCCH3)2][PF6],
have shown significant cytotoxicity against breast (MCF-7) and cervical (HeLa) cancer
cell lines.6

NH3

H3N
Pt

X
O

O

Y

Ru

O

Z

O

R

Figure 3.1. Structures of [(η6-arene)Ru(X)(Y)(Z)] (left), and carboplatin (right).

Much work is also being conducted to develop ruthenium catalysts that improve
reaction efficiency in an effort to advance the principles of green chemistry. Various
coordination complexes of ruthenium exhibit industrially-significant catalytic properties.
For example, the complex RuH2(PPh3)4 (Figure 3.2) catalyzes the conversion of nitriles
to amides,7 esterification using alcohols and nitriles,8 and the polymerization of nylon6,6,7 among other reactions. The most notable ruthenium-based catalysts, the Grubbs
catalysts (Figure 3.2), enable various olefinic metatheses such as in ring-opening
polymerization and ring closures.9 By using these catalytic synthetic methods,
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improvements can be made in various organic reactions’ atom efficiencies and their
selectivity.

PPh3

PCy3
Cl
Ru

PPh3

Ph3P
Ru
Ph3P

H
H

N

N
Ru

Cl

Cl

PCy3

Cl

PCy3

Figure 3.2. Structures of RuH2(PPh3)4 (left), Grubbs catalyst, 1st generation (Cy =
cyclohexane; middle), and Grubbs catalyst, 2nd generation (right).

The primary ruthenium source for organometallic and coordination chemistry is
ruthenium(III) chloride hydrate, used to synthesize the commonly-used synthons
RuCl2(PPh3)310 and polymeric [RuCl2(COD)]x11 (COD = 1,5-cyclooctadiene; Figure 3.3).
Use of RuCl2(PPh3)3 and [RuCl2(COD)]x in subsequent reactions results in complexes
that contain triphenylphosphine or COD ligands, substituents that are undesirable in
further substitution reactions due to their tendency to crowd available coordination sites
because of their steric bulk.

Another reported ruthenium starting material,

[Ru(NCCH3)6][ZnCl4]12 does not have the issues with sterically-bulky ligands in its
coordination sphere, but is an undesirable material to use in subsequent coordination
reactions, since competitive binding of the coordinating ligands may occur between the
ruthenium cation and the zincate anion.
The family of tris(acetonitrile) tris(pyrazolyl) ruthenium(II) complexes are of
great interest, since these would make excellent synthons for a variety of ruthenium
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Ph3P

Cl
Ru

Ph3P

Ru

PPh3
Cl

Cl
n

Cl

Figure 3.3. Structures of RuCl2(PPh3)3 (left) and [RuCl2(COD)]x (right).

chemistry.

However, there are few reports of the synthesis of these complexes.

Synthesis of Tp-type ruthenium(II) complexes of the formula [TpRRu(NCCH3)3][X] (R =
H, Me, iPr; X = PF6-, OTf-) requires multiple steps and the use of many chemicals, but
synthesis of [TpRu(NCCH3)3][PF6]13 (Scheme 3.1), [Tp*Ru(NCCH3)3][OTf]14 (Scheme
3.2), and [TpiPrRu(NCCH3)3][OTf]15 (Scheme 3.2) have all been reported. Interestingly,
there are no reports of syntheses of analogous Tpm-type ruthenium(II) complexes of the
formula [TpmRRu(NCCH3)3][(X)2] (R = H, Me, iPr, Ph; X = PF6-, OTf-). Closely related
Tpm-type ruthenium(II) complexes that have been reported also require many steps to
synthesize,

including

[TpmRuCl(NCCH3)2][PF6]6

[TpmRu(OH2)3][(OTs)2]16 (Scheme 3.3).

(Scheme

3.3)

and

This chapter presents a new method to

synthesize hexakis(acetonitrile) ruthenium(II) complexes containing uncoordinated
nonmetallic counteranions and tris(acetonitrile) tris(pyrazolyl)borato ruthenium(II)
complexes with reduced reaction times, and a general method to synthesize novel
tris(acetonitrile) tris(pyrazolyl)methano ruthenium(II) complexes (Figure 3.4).
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Figure 3.4. Structures of target ruthenium(II) complexes discussed in this chapter.

Results and Discussion
Synthesis and characterization of hexakis(acetonitrile) ruthenium(II) starting
materials.

The only reported syntheses of hexakis(acetonitrile) ruthenium(II) starting

materials are those of [Ru(NCCH3)6][(BF4)2] (1),20

reported in 1974, and

[Ru(NCCH3)6][ZnCl4],12 reported in 2001. Surprisingly, these complexes have not been
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utilized as starting materials for additional ruthenium chemistry; this is most likely
because 1 requires many steps to synthesize (Scheme 3.4) and the ruthenium(II) zincate
species contains a counteranion capable of ligand coordination that would cause
undesired competitive binding. Reported characterization was limited to IR and 1H NMR
spectroscopy, as well as elemental analysis, for both reported [Ru(NCCH3)6]2+ species.

Scheme 3.4

2
RuCl3 . 3 H2O

NBD

Mg

Cl

Ru

Ru

EtOH, reflux 24 h
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Using an improved synthetic method, two [Ru(NCCH3)6][(X)2] complexes (X =
BF4-; 1 and X = OTf-; 2) were prepared similarly to that of [Ru(NCCH3)6][ZnCl4],12 but
with a counteranion exchange step (with NaBF4 or NaOTf) after reduction of the
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ruthenium to remove the zincate anion. After workup, a light yellow solid is obtained
(Figure 3.5). Using this procedure, 1 and 2 were obtained in yields of 66% and 60%,
respectively, as compared to 80% for the previous preparation of 1 and 36% for the
zincate species. Overall, synthesis of 1 using this method is significantly shorter with
three fewer steps, and results in a product without a counterion capable of ligand
coordination (Table 3.1).

Zn

2 RuCl3 . 3 H2O

CH3CN, reflux 1 h

[Ru(NCCH3)6][ZnCl4]
+
RuCl2(NCCH3)4

4 NaX

2 [Ru(NCCH3)6][(X)2]
+ 4 NaCl + ZnCl2

reflux 16 h

X = BF4- , OTf-

Figure 3.5. Synthesis of ruthenium(II) starting materials.

Table 3.1. List of synthetic parameters for selected ruthenium(II) acetonitrile complexes.
Steps

Reaction
Time

% Yield

Ref

[Ru(NCCH3)6][(BF4)2]

4

60 h

80

20

[Ru(NCCH3)6][ZnCl4]

1

2h

36

12

[Ru(NCCH3)6][(BF4)2] (1)

1

13 h

66

This work

[TpRu(NCCH3)3][PF6]

3

33 h

70

13

[TpRu(NCCH3)3][BF4] (3)

1

1h

56

This work

[Tp*Ru(NCCH3)3][OTf]

7

46 h

72

14

[Tp*Ru(NCCH3)3][OTf] (4)

1

30 min

65

This work

[TpPhRu(NCCH3)3][OTf] (5)

1

15 min

53

This work

[Tpm*Ru(NCCH3)3][(BF4)2] (6)

1

12 h

72

This work

[TpmPhRu(NCCH3)3][(OTf)2] (7)

1

8h

22

This work

Complex
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Characterization of 1 and 2 matches reported values for 1H NMR and IR
spectra.12,20

In both cases, the bound acetonitrile shifts downfield in the 1H NMR

spectrum to δ 2.68 and 2.52, respectively, compared to δ 2.10 for unbound acetonitrile.
The IR spectra for both 1 and 2 show nitrile stretching frequencies of 2326 cm-1 and 2373
cm-1, consistent with reported values of 2300 cm-1 and 2325 cm-1 for nitrile stretches of 1
and the ruthenium(II) zincate species. This shift to higher energies upon ruthenium(II)
binding relative to free acetonitrile (2250 cm-1) indicates an increased nitrile bond
strength due to donor bond formation upon ruthenium(II) complexation.
Single crystal X-ray diffraction data was collected for [Ru(NCCH3)6][(BF4)2] (1),
which crystallized as colorless cubes by slow vapor diffusion of diethyl ether into an
acetonitrile solution, and compared to the reported structure of [Ru(NCCH3)6][ZnCl4].12
Selected bond lengths for 1 are summarized in Table 3.2, and its structure is shown in
Figure 3.6.

1 crystallized with a unit cell in the monoclinic P21/c with unit cell

dimensions of a = 8.0993(16), b = 8.1969(16), c = 15.877(3) Å, α = 90.00, β = 92.78(3), γ
= 90.00°, whereas the zincate species crystallized with a unit cell in the trigonal R-3
space group with larger unit cell dimensions than 1 (a = 11.744, b = 11.744, c = 30.932
Å, α = 90.000, β = 90.000, γ = 120.00°).

Similar average Ru-N bond distances of

2.03(7) Å were observed for the two [Ru(NCCH3)6]2+ species. The packing structure of 1
shows a close contact between F(2) and the H on C(6) (2.50 Å) that is smaller than the
sum of their van der Waal radii (2.67 Å) and can be seen in the packing diagram viewed
along the a-axis (Figure 3.7).

No interactions are observed between ions for the

[Ru(NCCH3)6][ZnCl4] structure.12

With

56

an

improved

synthetic

method

for

Ru[(NCCH3)6]2+ species 1 and 2, these materials can be used as synthons to synthesize
tris(acetonitrile) ruthenium(II) complexes with trinitrogen donor ligands.

Table 3.2. Selected bond lengths [Å] and angles [º] for [Ru(NCCH3)6][(BF4)2] (1).
_____________________________________________________________
Ru(1)-N(2)
2.023(3)
Ru(1)-N(3)
2.024(3)
Ru(1)-N(1)
2.028(3)
N(2)-C(5)
1.133(4)
N(3)-C(7)
1.130(4)
N(1)-C(3)
1.137(4)
F(2)-B(1)
1.395(6)
F(3)-B(1)
1.398(6)
F(4)-B(1)
1.397(5)
F(1)-B(1)
1.390(6)
C(7)-C(8)
1.449(5)
C(3)-C(4)
1.461(5)
C(6)-C(5)
1.451(5)
N(2)-Ru(1)-N(3)
90.14(11)
N(2)-Ru(1)-N(1)
89.30(11)
N(3)-Ru(1)-N(1)
91.79(11)
C(5)-N(2)-Ru(1)
175.8(3)
C(7)-N(3)-Ru(1)
174.6(3)
C(3)-N(1)-Ru(1)
173.4(3)
F(1)-B(1)-F(2)
108.2(4)
F(1)-B(1)-F(4)
110.8(4)
F(2)-B(1)-F(4)
108.6(4)
F(1)-B(1)-F(3)
109.9(4)
F(2)-B(1)-F(3)
109.7(4)
F(4)-B(1)-F(3)
109.5(4)
N(3)-C(7)-C(8)
179.4(4)
N(1)-C(3)-C(4)
178.0(4)
N(2)-C(5)-C(6)
178.7(4)
_____________________________________________________________
Symmetry transformations used to generate equivalent atoms: -x+2,-y,-z+2
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Figure 3.6. Crystal structure diagram of [Ru(NCCH3)6][(BF4)2]. Density surfaces show
50% probability ellipsoids.

Synthesis

and

characterization

of

the

tris(pyrazolyl)borato-type

tris(acetonitrile) ruthenium(II) complexes. The only reported complexes of the formula
[TpRRu(NCCH3)3]+

are

[TpRu(NCCH3)3][PF6],13

[Tp*Ru(NCCH3)3][OTf],14

and

[TpiPrRu(NCCH3)3][OTf].15 These complexes have not been utilized as starting materials
for other ruthenium chemistry, likely because of the time and number of steps required to
synthesize the materials (Schemes 3.1 and 3.2). Using [Ru(NCCH3)6]2+ complexes 1 and
2 as starting materials, complexes of the formula
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Figure 3.7. Packing diagram of [Ru(NCCH3)6][(BF4)2] viewed along the a-axis of the
unit cell.
[TpRRu(NCCH3)3][X] (R = H, Me, Ph; X = BF4, OTf) were synthesized according to a
new procedure (Figure 3.8; Table 3.1).
The first complexes made using the improved procedure, [TpRu(NCCH3)3][BF4]
(3) and [Tp*Ru(NCCH3)3][OTf] (4), have yields of 56% and 65%, respectively as
compared to reported yields of 70% and 72%, respectively.13,14 However, the improved
synthetic method significantly cuts the number of steps (by two for 3, six for 4) and the
amount of time to obtain a final product (by 35 h and 44 h for 3 and 4, respectively) with
only an average yield reduction of 15%. Previous reports have characterized 3 using IR,
1

H, and 13C{1H} NMR spectroscopies as well as elemental analysis,13 whereas 4 was
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Figure 3.8. Synthesis of [TpRRu(NCCH3)3][X].

previously characterized using

1

H NMR spectroscopy and elemental analysis.14

Characterization of 3 and 4 match reported values for 1H NMR spectra, and the 19F{1H}
NMR spectra shows a single resonance for 3 and 4 (δ -148.3 and -77.8, respectively),
indicating that the counteranion is not coordinated to the ruthenium center. The IR
spectra of both 3 and 4 showed a vibrational energy for the bound acetonitrile ligands at
2344 cm-1 and 2472 cm-1, respectively, compared to 2326 and 2373 cm-1 for
[Ru(NCCH3)6]2+ species 1 and 2, respectively. The increased nitrile bond energy for both
3 and 4 indicates stronger σ-bonding of the bound acetonitriles occurs upon addition of a
Tp-type ligand.
A new complex, [TpPhRu(NCCH3)3][OTf] (5), was also synthesized using this
new procedure with a yield of 53%. In the 1H NMR spectrum for 5, two separate
resonances are now observed for both the ortho and meta protons on the phenyl
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substituents, indicating that the corresponding protons on the phenyl rings are not
equivalent. The

19

F{1H} NMR spectrum shows a slight downfield shift to δ -77.7 as

compared to δ -79.3 for 2, indicating that the triflate counteranion is still not coordinated
to the ruthenium center, although there may be some competition in binding between the
triflate and the TpPh ligand. The IR spectrum of 5 showed an decreased vibrational
energy for the bound acetonitrile ligands of 2345 cm-1 compared to 2373 cm-1 for
[Ru(NCCH3)6]2+ species 2, similar to the shift observed for the Tp* analog 4. This result
shows stronger backbonding of the acetonitriles to the ruthenium center, even with the
increased steric bulk on the TpPh ligand.
Synthesis

and

characterization

tris(acetonitrile) ruthenium(II) complexes.

of

new

tris(pyrazolyl)methane-type

Two new complexes of the formula

[TpmRRu(NCCH3)3]2+ were synthesized using the same improved procedure for
synthesizing

[TpRRu(NCCH3)3]+

the

complexes.

Synthesis

of

[Tpm*Ru(NCCH3)3][(BF4)2] (6) and [TpmPhRu(NCCH3)3][(OTf)2] (7) takes only one
step and 16 h (including work-up) to prepare (Figure 3.9) with yields of 72% and 22%,
respectively (Table 3.1). The 1H NMR spectra for 6 and 7 show the same pattern of
resonances observed for analogous Tp* and TpPh ruthenium complexes, 4 and 5,
respectively. As seen for these TpR ruthenium complexes, the resonance for the bound
acetonitrile ligands shifts downfield (δ 1.60 and 2.62 for 6 and 7, respectively), compared
to δ 2.68 and 2.52 for the bound acetonitrile in [Ru(NCCH3)6]2+ starting materials 1 and
2, respectively. The
analogs 4. The

19

13

C{1H} NMR spectrum of 6 show similar shifting to the TpR

F{1H} NMR spectra for 6 and 7 indicate that the counteranion is not
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coordinated to the ruthenium center, as their 19F resonances did not shift compared to the
resonances of the [Ru(NCCH3)6]2+ starting materials.
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N

CH3OH, reflux 18 h

N
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2X
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N
N
R Ru

H3CCN
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N
R
NCCH3

NCCH3

6: R = Me, X = BF47: R = Ph, X = OTf-

Figure 3.9. Synthesis of [TpmRRu(NCCH3)3][(X)2].

The IR spectra of [(TpmR)Ru(NCCH3)3][(X)2] complexes 6 (R = Me, X = BF4-)
and 7 (R = Ph, X = OTf-) both show a nitrile stretching frequency of 2345 cm-1,
compared to 2326 and 2373 cm-1 for [Ru(NCCH3)6]2+ species 1 and 2, respectively. The
increased nitrile bond energy for 6 indicates that stronger σ-bonding of the bound
acetonitrile ligands occurs upon addition of a Tpm* ligand, whereas the decreased nitrile
bond energy for 7 indicates stronger backbonding of the bound acetonitrile ligands to the
ruthenium center upon adding a TpmPh ligand.
Many attempts were made to synthesize [TpmRu(NCCH3)3][(X)2] (X = BF4, OTf)
without success.

The synthetic procedure outlined in Figure 3.9 was attempted in
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multiple solvents (acetonitrile, methanol, ethanol, THF, dichloromethane, DMF, toluene),
varying reaction times (4 h to 60 h), and varying temperatures (from room temperature to
reflux). All 1H NMR spectra of the reaction mixtures indicated no coordination of the
Tpm ligand to ruthenium(II).
Comparison of the syntheses of tris(pyrazolyl) ruthenium(II) complexes. The
data in Table 3.2 clearly shows that synthesis of the reported complexes 3 – 7 require a
large number of steps and long times, making these synthons less desirable to use in
ruthenium chemistry than the commonly used synthons such as TpRuCl(COD),17
TpRuCl(PPh3)2,18 and [TpmRuCl(PPh3)2][BF4]19 (Figure 3.10). In contrast, complexes of
the formula [TpRRu(NCCH3)3][X] (R = H, Me, Ph; X = BF4, OTf) synthesized according
to the new procedure (Figure 3.5) require only one step and 5 h preparation times. This
procedure

has

also

enabled

synthesis

of

TpmR

new

complexes

[Tpm*Ru(NCCH3)3][(BF4)2] and [TpmPhRu(NCCH3)3][(OTf)2] in one step with up to
16 h preparation times.
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Figure 3.10. (Tp)RuCl(COD) (left), (Tp)RuCl(PPh3)2 (middle), and
[(Tpm)RuCl(PPh3)2][BF4] (right).
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The reaction times needed to synthesize the TpR (15 min to 1 h) ruthenium(II)
complexes are surprisingly fast considering the inert nature of ruthenium(II), and they
follow a trend based on the ligand charge and their steric bulk. Charged trinitrogen donor
ligands expectedly require less reaction time than uncharged donors (8 to 12 h for the
Tpm* and TpmPh complexes, respectively), thus in increasing reaction time, TpPh < Tp* <
Tp < TpmPh < Tpm*. The syntheses also decrease in reaction time as the steric bulk of
the trinitrogen donor is increased in the order TpPh < Tp* < Tp and TpmPh < Tpm*.
Electrochemistry of ruthenium(II) complexes. Cyclic voltammetry was performed
on ruthenium(II) acetonitrile-containing complexes 1 and 3 – 7 to determine how
changing the charge and steric bulk of the Tp-type ligands affects the Ru2+/3+ redox
potentials (Table 3.3). The Ru2+/3+ potentials indicate that the charge on Tp-type ligands
has a significant effect on Ru2+/3+ electrochemical potentials. The Tp* analog 4 (0.498 V
vs. NHE) has a slightly higher potential than its Tpm* analog, 6 (0.390 V), and the TpPh
analog 5 (0.595 V) has a slightly higher potential than its TpmPh analog 7 (0.552 V),
indicating that charged Tp-type ligands better stabilize ruthenium(III) relative to
ruthenium(II). These results agree with the nitrile bond frequencies for 4 and 6, (2472
cm-1 and 2345 cm-1, respectively) indicating that σ-donor bonding of the bound
acetonitriles in 4 is more significant than in 6.
The Ru2+/3+ potentials in Table 3.3 also indicate that [TpRu(NCCH3)3]+ (3) has a
lower Ru2+/3+ potential (0.489 V vs. NHE) than both the Tp* analog 4 (0.498 V) and the
TpPh analog 5 (0.595 V). A similar trend of increasing potentials is also observed for the
neutral Tpm* complex 6 (0.390 V) and the TpmPh complex 7 (0.552 V). Comparison of
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Table 3.3. Ru2+/3+ potentials for target complexes (E vs. NHE).
Epa (V)

Epc (V)

∆E (V)

E½, (V)

[Ru(NCCH3)6][(BF4)2] (1)

0.410

0.623

0.213

0.517

[TpRu(NCCH3)3][BF4] (3)

0.352

0.625

0.273

0.489

[Tp*Ru(NCCH3)3][OTf] (4)

0.415

0.580

0.165

0.498

[TpPhRu(NCCH3)3][BF4] (5)

-0.457

1.65

2.11

0.595

[Tpm*Ru(NCCH3)3][(BF4)2] (6)

0.099

0.681

0.582

0.390

[TpmPhRu(NCCH3)3][(BF4)2] (7)

-0.500

1.603

2.10

0.552

Complex

the Ru2+/3+ potentials of these complexes shows that the steric bulk of analogous TpR-type
ligands (R = H, Me, Ph) has a modest effect on the redox potential of ruthenium(II),
stabilizing ruthenium(II) relative to ruthenium(III), where TpPh < Tp* < Tp and TpmPh <
Tpm*.

A similar trend was also observed for the Tp-type complexes of copper(I)

complexes of the formula TpRCu(NCCH3) and [TpmRCu(NCCH3)][X] (R = H, Me, iPr; X
= Cl, BF4).18 Overall, using Tp-type ligands of varying steric bulk can change the Ru2+/3+
potential by over 200 mV.
Conclusions.

An improved synthetic method has been developed for

[Ru(NCCH3)6]2+ starting materials and the Tp-type ruthenium(II) tris(acetonitrile) series
of complexes that only requires one step in the synthetic procedure. Using a similar
synthetic pathway, a novel series of Tpm-type ruthenium(II) tris(acetonitrile) complexes
were synthesized that may be used for comparative purposes with its Tp-type analogs.
This new synthetic method to synthesize these Tp- and Tpm-type tris(acetonitrile)
ruthenium(II) complexes will help open up ruthenium chemistry in catalysis and DNA
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binding, where these complexes can be used as synthons.
Understanding the redox chemistry of ruthenium with nitrogen donor ligands can
give us insight into how ruthenium complexes behave in biological systems.
Coordination of Tp-type ligands to ruthenium can significantly alter Ru2+/3+
electrochemical potentials from 0.390 V to 0.595 V. Steric bulk, rather than the charge
of the Tp-type ligands, is the predominant factor that controls Ru2+/3+ redox potential.
This ability to stabilize either oxidation state of ruthenium (+2 or +3) may be used to tune
catalytic reactions and provide insight into how ruthenium may behave when bound to
DNA.

Experimental Methods
General air-sensitive techniques under argon were used to synthesize the
complexes unless otherwise stated.

1

H,

13

C{1H}, and

19

F{1H} NMR spectra were

obtained using 300 and 500 MHz Bruker-AVANCE NMR spectrometers.

1

H and

13

C{1H} NMR chemical shifts are reported in δ relative to tetramethylsilane (TMS) and

referenced to solvent. 19F{1H} NMR spectra were externally referenced to CCl3F (δ 019).
Infrared spectra were obtained using Nujol mulls on KBr salt plates with a Magna 550 IR
spectrometer. Abbreviations used in the description of vibrational data are as follows: vs,
very strong; s, strong; m, medium; w, weak; b, broad. Electrospray ionization mass
spectrometry (ESI-MS) was conducted using a QSTAR XL Hybrid MS/MS System from
Applied Biosystems via direct injection of sample (0.05 mL/min flow rate) into a Turbo
Ionspray ionization source. Samples were run under positive mode in methanol, with
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ionspray voltage of 5500 V, and in TOF scan mode. Peak envelopes match theoretical
calculations for their ions.
Elemental analyses were performed in-house on a Perkin Elmer 2400 Series II
CHNS/O Elemental analyzer.

The elemental analysis for the acetonitrile-containing

ruthenium complexes (1 – 7) were within 3% of the values calculated for the tetrahedral
complexes resulting from the loss of two acetonitrile ligands.

This loss of two

acetonitrile ligands resulted from drying in vacuo for approximately 4 h., as has been
previously reported for the iron(II) triflate complex.20
Ruthenium(III) chloride hydrate was purchased from Pressure Chemical;
potassium borohydride, 3,5-dimethylpyrazole, sodium tetrafluoroborate, and tetra-nbutylammonium bromide were purchased from Alfa Aesar; diethyl ether was purchased
from Fisher/Acros; methanol and acetonitrile were purchased from Mallinkrodt;
chloroform was purchased from BDH; sodium triflate was purchased from TCI; and dry
methanol was purchased from Burdick. KTp, KTp*,21 KTpPh,22 Tpm,23 Tpm*,23 and
TpmPh 24 were synthesized using reported procedures.
Syntheses of [Ru(NCCH3)6][(BF4)2] (1) and [Ru(NCCH3)6][(OTf)2] (2). A new
method was used to synthesize 1. Zinc powder (0.23 g, 3.60 mmol) was added to a
solution of ruthenium(III) chloride hydrate (2.0 g, 7.15 mmol) in acetonitrile (150 mL)
and the mixture was heated to reflux for 30 min. The mixture turned from black to
yellow during this time. The reaction mixture was filtered, sodium tetrafluoroborate
(1.65 g, 15.0 mmol) was added to the filtrate, and the solution was heated to reflux for an
additional 12 h, during which time a white precipitate formed. The solution was again
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filtered and the solvent was removed in vacuo. The light yellow powder was washed
with ether to remove any excess zinc salts. Crystals of X-ray quality were grown by
vapor diffusion of diethyl ether into acetonitrile. Yield: 2.47 g (66%). The synthesis for
2 is the same as for 1, except that sodium triflate (2.59 g, 15.0 mmol) was added instead
of sodium tetrafluoroborate. Yield: 2.78 g (60%). 1H NMR (d6-DMSO) and IR (Nujol,
cm-1) spectra of 1 and 2 match reported values.12,21 For 1: 13C{1H} NMR (d6-DMSO):
δ 4.01 (CH3CN), 126.9 (CH3CN).

19

F{1H} NMR (d6-DMSO): δ -148.3 (s). Anal. Calc.

for RuC8H10F8N4B2: C, 21.88; N, 12.76; H, 2.74. Found: C, 22.92; N, 13.32; H, 13.32.
For 2:

13

C{1H} NMR spectrum identical to 1.

19

F{1H} NMR (d6-DMSO): δ -79.3 (s).

Anal. Calc. for RuC10H10S2F6O6N4: C, 21.30; N, 9.94; H, 2.13. Found: C, 20.64; N, 8.11;
H, 2.12.
Synthesis of [TpRu(NCCH3)3][BF4] (3).

We have synthesized this previously

reported complex13 using our improved method. KTp (88.1 mg, 0.35 mmol) dissolved in
methanol (10 mL) was added dropwise using a cannula to a solution of 1 (200 mg, 0.38
mmol) in methanol (25 mL), and the solution was stirred for 30 min. A white precipitate
formed and was separated using cannula filtration. The filtrate was concentrated by
reducing the volume of the solvent to 10 mL, and a dull white solid precipitated. Ether
(15 mL) was added to facilitate precipitation, and the light yellow powder was separated
by cannula filtration, washed with ether (10 mL), and dried in vacuo. Yield: 103 mg
(56%). 1H and 13C{1H} NMR (d6-DMSO) and IR (Nujol, cm-1) spectra match previously
reported values.13

19

F{1H} NMR (d6-DMSO): δ -148.3 (s).

Anal. Calc. for

RuC11H13F4N7B: C, 27.39; N, 22.19; H, 2.94. Found: C, 28.95; N, 20.4; H, 3.05.
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Synthesis of [Tp*Ru(NCCH3)3][OTf] (4). We have made this previously reported
complex14 using our improved method. Synthesis of 4 is similar to the method used to
synthesize complex 3, except that [Ru(NCCH3)6][(OTf)2] (2) was used instead of
[Ru(NCCH3)6][(BF4)2] (1), and KTp* (101 mg, 0.30 mmol) was used instead of KTp. A
light yellow powder was obtained after work-up. Yield: 235 mg (65%). 1H and 13C{1H}
NMR (d6-DMSO) spectra match previously reported values.14

19

F{1H} NMR (d6-

DMSO): δ -77.8 (s). IR (Nujol, cm-1): 719 m, 759 w, 1048 s, 1110 s, 1207 m, 1261 m,
1303 s, 1403 s, 1459 s, 1500 m, 2344 w, 2374 w, 2472 m, 2854 s, 2923 s, 3117 w, 3394
w. Anal. Calc. for RuC18H25SF3O3N7B: C, 36.73; N, 16.67; H, 4.25. Found: C, 35.76; N,
17.65; H, 4.20.
Synthesis of [TpPhRu(NCCH3)3][OTf] (5). KTpPh (212 mg, 0.30 mmol) dissolved
in a 1:1 solution of methanol/acetone (15 mL) was added dropwise using a cannula to a
solution of 2 (100 mg, 0.30 mmol) in methanol (15 mL), and the solution was stirred for
15 min, during which time a white precipitate formed. The reaction was dried in vacuo
and the residue was extracted with acetone. The mixture was filtered and the filtrate was
dried in vacuo to yield a light yellow powder.

Yield: 86 mg (53%).

1

H NMR (d6-

DMSO): δ 2.70 (s, 9H, CH3CN), 6.66 (s, 3H, 4-pz), 7.03 (br s, 6H, p-Ph), 7.20 (s, 3H),
7.31 (t, 6H, m-5-Ph), 7.46 (br t, 6H, m-3-Ph), 7.79 (d, 6H, o-5-Ph), 7.81 (br d, 6H, o-3Ph).

19

F{1H} NMR (d6-DMSO): δ -77.8 (s). IR (Nujol, cm-1): 688 w, 754 m, 800 w, 975

w, 1031 m, 1076 w, 1170 w, 1261 m, 1377 w, 1459 vs, 1655 w, 1686 w, 2345 w, 2373 w,
2854 vs, 2924 vs, 3448 w. Anal. Calc. for RuC48H36SF3O3N7B: C, 59.63; N, 10.14; H,
3.83. Found: C, 59.75; N, 10.91; H, 3.80.
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Synthesis of [Tpm*Ru(NCCH3)3][(BF4)2] (6). Tpm* (119 mg, 0.40 mmol) was
added to a solution of 1 (200 mg, 0.38 mmol) in methanol (25 mL), and the solution was
heated to reflux for 12 h. The reaction mixture was filtered and the solvent was removed
in vacuo. The residue was washed with ether (10 mL) and dried in vacuo to yield a light
brown solid. Yield: 190 mg (72%). 1H NMR (d6-DMSO): δ 1.60 (s, 9H, CH3CN), 2.66
(s, 9H, 3-Me), 2.72 (s, 9H, 5-Me), 6.33 (s, 3H, 4-pz), 8.09 (s, 1H, Hapi).

13

C{1H} NMR

(d6-DMSO): δ 3.95 (CH3CN), 11.2 (3-Me), 12.0 (5-Me), 67.5 (Capi), 108.2 (C-4), 127.0
(CH3CN), 143.7 (C-3), 152.9 (C-5).

19

F{1H} NMR (d6-DMSO): δ -148.3 (s). Mass

spectrum (ESI-MS): m/z 431.2 [(Tpm*)Ru(OMe)]+. IR (Nujol, cm-1): 724 m, 760 w,
1058 s, 1282 w, 1377 s, 1459 vs, 2344 w, 2373 w, 2855 s, 2923 s, 3248 w. Anal. Calc.
for RuC18H25F8N4B2: C, 35.20; N, 15.97; H, 4.07. Found: C, 34.57; N, 14.17; H, 3.49.
Synthesis of [TpmPhRu(NCCH3)3][(OTf)2] (7). TpmPh (121 mg, 0.30 mmol) was
added to a solution of 2 (100 mg, 0.30 mmol) in THF (25 mL), and the solution was
stirred for 8 h at room temperature. The solution was filtered and the filtrate was dried in
vacuo. The residue was extracted with dichloromethane, filtered, and the filtrate dried in
vacuo to yield a yellow solid. Yield: 40 mg (22%). 1H NMR (d6-DMSO): δ 2.69 (s, 9H,
CH3CN), 7.14 (s, 3H, 4-pz), 7.20-7.49 (m, 18H, m-, p-Ph), 7.85-7.91 (m, 12H, o-Ph),
7.97 (s, 1H, Hapi).

19

F{1H} NMR (d6-DMSO): δ -78.8 (s). IR (Nujol, cm-1): 576 w, 638

w, 694 s, 761 m, 799 s, 917 w, 954 w, 1028 s, 1094 s, 1261 s, 1377 w, 1459 vs, 1655 w,
1686 w, 2344 w, 2373 w, 2854 vs, 2924 vs. Anal. Calc. for RuC50H36S2F6O6N7: C,
53.75; N, 8.78; H, 3.31. Found: C, 52.04; N, 8.54; H, 3.83.
X-ray data collection and structural determination of [Ru(NCCH3)6][(BF4)2] (1).
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Single crystals of [Ru(NCCH3)6][(BF4)2] were grown from slow vapor diffusion of
diethyl ether into an acetonitrile solution and were mounted on a glass filament with
silicon grease and immediately cooled to 168.15 K in a cold nitrogen gas stream.
Intensity data were collected using a Rigaku Mercury CCD detector and an AFC-8S
diffractometer. The space group P21/c was determined from the observed systematic
absences. Data reduction including the application of Lorentz and polarization effects
(Lp) and absorption corrections used the CrystalClear28 program. The structure was
solved by direct methods and subsequent Fourier difference techniques, and refined
anisotropically, by full-matrix least squares, on F2 using SHELXTL 6.10.29 The quantity
minimized by the least square program was Σw = (Fo2 - Fc2)2 where w = {[σ2(Fo2)] +
(0.0422P)2 + 1.87P]} where P = (Fo2) + 2Fc2)/3]. In the final cycle of least squares,
independent anisotropic displacement factors were refined for the non-hydrogen atoms
and the methyl hydrogen atoms were fixed in “idealized” positions with C-H = 0.96 Å.
Their isotropic displacement parameters were set equal to 1.5 times Ueq of the attached
carbon atom. The largest peak in the final Fourier difference map (0.88 e.Å-3) was
located 1.61 Å from N1 and the lowest peak (-0.49 e.Å-3) was located at a distance of
0.86 Å from Ru1. Final refinement parameters for the structure of [Ru(NCCH3)6][(BF4)2]
(1) are given in Table 3.4.
Electrochemical studies of synthesized ruthenium(II) complexes.

Cyclic

voltammetry (CV) experiments were carried out using CHI Electrochemical analyzer and
employed a three-electrode cell consisting of glassy carbon working electrode, a
Ag/AgCl reference electrode, and a platinum wire auxiliary electrode. The glassy carbon
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electrode was polished with alumina prior to each trial. CV experiments were conducted
in acetonitrile containing 0.1 mM complex and 0.1 M tetra-n-butyl ammonium
hexafluorophosphate (TBAPF6) at a scan speed of 0.1 V/s from -1.25 V to 1.25 V.
Solutions were deoxygenated with dry nitrogen gas and maintained under a blanket of
nitrogen

during measurements,

and

voltammagrams

were

referenced

to

the

ferrocene/ferricenium couple (Fc+/0) at 0.46 V.30 Formal potentials were evaluated as E½
= (Epa+Epc)/2, where Epa and Epc are anodic and cathodic peak potentials. Peak potential
separations were evaluated as ∆E = |Epa-Epc|.

Table 3.4. Crystallographic data and structure refinement for [Ru(NCCH3)6][(BF4)2] (1).
Empirical formula
Formula weight (g/mol)
Temperature (K)
Wavelength (Å)
Crystal system
Space group
Unit cell dimensions
a (Å)
b (Å)
c (Å)
α (deg)
β (deg)
γ (deg)
3
Volume (Å )
Z
Calculated density (mg/m3)
Absorption coefficient (mm-1)
F(000)
Crystal size (mm)
Crystal color and shape
Θ range for data collection (deg)
Limiting indices

Reflections collected
Independent reflections
Completeness to Θ
Max. transmission
Min. transmission
Refinement method
Data / restraints / parameters
Goodness of fit on F2
Final R indices (I > 2σ(I))
R1
wR2
R indices (all data)
R1
wR2
Largest diff. peak and hole

C12H18B2F8N6Ru
521.01
168.15
0.71073
Monoclinic
P21/c
8.0993(16)
8.1969(16)
15.877(3)
90.00
92.78(3)
90.00
1052.9(4)
2
1.643
1.048
516
0.30 × 0.25 × 0.22
colorless prism
3.51 < θ < 26.33°
-9 < h < 10
-10 < k < 10
-19 < l < 19
8579
2126
26.33 (99 %)
0.8397
0.7904
Full-matrix least-squares on F2
2126 / 0 / 136
1.112
0.0362
0.0862
0.0448
0.0938
0.876 and -0.489 e.Å-3
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